[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-126569-105":59,"doc-detail-126569-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","decancer-machine-learning-framework-tailored-to-liquid-biopsy-based-cancer-detection-and-biomarker-signature-selection","DEcancer - Machine learning framework tailored to liquid biopsy based cancer detection and biomarker signature selection","","DEcancer is a tailored machine learning pipeline for liquid biopsy analysis designed to address limitations of existing studies, including insufficient biomarker selection, weak cancer detection performance, and limited validation. Using a test set from a published cohort of 1,005 patients across 8 cancer types and 812 cancer-free individuals, it raises stage 1 detection sensitivity across cancer types from 48% to 90%. In an independent lung proteomics cohort, performance using a 14–43 protein panel matches that of 1,000 original proteins, supporting clinical blood-based testing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/decancer-machine-learning-framework-tailored-to-liquid-biopsy-based-cancer-detection-and-biomarker-signature-selection/126569/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/decancer-machine-learning-framework-tailored-to-liquid-biopsy-based-cancer-detection-and-biomarker-signature-selection/126569.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-19","2026-08-05",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does DEcancer aim to solve in liquid biopsy studies?","Question",{"text":112,"@type":113},"Existing liquid biopsy studies often lack parsimonious biomarker selection, show poor cancer detection performance, and do not provide sufficient validation and testing. DEcancer is built to address these gaps.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How much does DEcancer improve stage 1 cancer detection sensitivity across cancer types?",{"text":117,"@type":113},"In a test set of 1,005 patients across 8 cancer types, DEcancer increases stage 1 detection sensitivity across cancer types from 48% to 90%.",{"name":119,"@type":110,"acceptedAnswer":120},"How does DEcancer perform when using a reduced biomarker panel in lung cancer proteomics data?",{"text":121,"@type":113},"For a lung cancer proteomics cohort, DEcancer using a 14–43 protein panel achieves performance comparable to using 1,000 original proteins.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},126569,1785933385,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":129,"read_time":144},13056712833777,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","iScience  \nll  \nOPEN ACCESS  \nArticle  \nDEcancer: Machine learning framework tailored to liquid biopsy based cancer detection and biomarker signature selection  \nAndreas Halner, Luke Hankey, Zhu Liang, ... , Benedikt M Kessler, Junetha Syed, Peter Jianrui Liu  \n[a.halner@oxcan.org](a.halner@oxcan.org) (A. H.)  \n[p.liu@oxcan.org](p.liu@oxcan.org) (P.J. L.)  \nHighlights  \nDEcancer multi-cancer detection over double sensitivity of existing cited approaches  \nDEcancer successfully identifies distinct cancer types  \nDEcancer selects a succinct panel of biomarkers indicative of cancer type, including lung  \nDEcancer provides a foundation for clinical blood-based tests for cancer detection  \nHalner et al. , iScience 26 , 106610  \nMay 19, 2023 ª 2023 The Authors.  \n[https://doi.org/10.1016/](https://doi.org/10.1016/)[ ](https://doi.org/10.1016/)[j.isci.2023.106610](j.isci.2023.106610)  \niScience  \nll  \nOPEN ACCESS  \nArticle  \nDEcancer: Machine learning framework tailored to liquid biopsy based cancer detection and biomarker signature selection  \nAndreas Halner,1,4,* Luke Hankey, 1 Zhu Liang, 1 Francesco Pozzetti, 1 Daniel Szulc, 1 Ella Mi, 1 Geoffrey Liu,2 Benedikt M Kessler,3 Junetha Syed,1 and Peter Jianrui Liu1,*  \nSUMMARY  \nCancer is a leading cause of mortality worldwide. Over 50% of cancers are diagnosed late, rendering many treatments ineffective. Existing liquid biopsy studies demonstrate a minimally invasive and inexpensive approach for disease detection but lack parsimonious biomarker selection, exhibit poor cancer detection performance and lack appropriate validation and testing. We established a tailored machine learning pipeline, DEcancer, for liquid biopsy analysis that addresses these limitations and improved performance. In a test set from a published cohort of 1,005 patients including 8 cancer types and 812 cancer-free individuals, DEcancer increased stage 1 cancer detection sensitivity across cancer types from 48 to 90% . In addition, with a test set cohort of patients from a high dimensional proteomics dataset of 61 lung cancer patients and 80 cancer-free individuals, DEcancer’s performance using a 14-43 protein panel was comparable to 1,000 original proteins. DEcancer is a promising tool which may facilitate improved cancer detection and management.  \nINTRODUCTION  \nCancer is among the leading cause of mortality worldwide, accounting for 10 million deaths per annum.1 Early detection through screening and monitoring of the most common cancers such as breast, colorectal, and prostate cancers have significantly helped to reduce mortality and enabled treatments with curative intent.2 However, many cancers such as lung and liver cancer that traditionally lacked effective early detection approaches remain among malignancies that account for the highest proportion of cancer related deaths globally.1 For example, lung cancer, though not the most prevalent, is the leading cause of cancer mortality worldwide in men and second in women.1 ,3 Unfortunately, the majority of lung cancers are diagnosed at a late stage because most patients remain asymptomatic until late disease, and only 30% are diagnosed at stage 1 .3 The five-year survival rate for stage 1 lung cancer is 65% and drastically decreases to 5% by stage 4 .3 Therefore, late detection is a main driving factor for lung malignancies that account for the highest cancer mortality. In contrast, breast cancer being the most common cancer in women, has an overall five-year survival rate of 90% because the majority of breast cancers are detected at an early localized stage.4 The wide adoption of mammography for screening has enabled a paradigm shift in the early detection of breast cancer, and hence improved patient survival and outcome.5 As with most cancers, there is a direct correlation between early detection and improved survival and outcome. Therefore, early detection and scalable screening approaches are critical to improving survival in cancers that continue to have a hig","cbCailV2pFcHloqA","https://ap.wps.com/l/cbCailV2pFcHloqA","pdf",4431334,18,"English","# Highlights\n# Summary\n# Introduction\n## Liquid biopsy for early cancer detection\n## Limits of existing multi-analyte tests","[{\"question\":\"What problem does DEcancer aim to solve in liquid biopsy studies?\",\"answer\":\"Existing liquid biopsy studies often lack parsimonious biomarker selection, show poor cancer detection performance, and do not provide sufficient validation and testing. DEcancer is built to address these gaps.\"},{\"question\":\"How much does DEcancer improve stage 1 cancer detection sensitivity across cancer types?\",\"answer\":\"In a test set of 1,005 patients across 8 cancer types, DEcancer increases stage 1 detection sensitivity across cancer types from 48% to 90%.\"},{\"question\":\"How does DEcancer perform when using a reduced biomarker panel in lung cancer proteomics data?\",\"answer\":\"For a lung cancer proteomics cohort, DEcancer using a 14–43 protein panel achieves performance comparable to using 1,000 original proteins.\"}]","DEcancer - Machine learning framework tailored to liquid biopsy based cancer detection and biomarker signature selection | PDF",45]